The Problem
Heart disease remains the leading cause of death worldwide, with an estimated 17.9 million deaths each year.
Regenerative medicine is a cutting-edge and rapidly growing field focused on drug design, cell-based therapies, and tissue engineering strategies that harness the innate power of the body’s own cells to promote preservation and repair of tissues and organs after injury or disease.
Our Solutions
Samba Biologics has developed biologic tools and treatments that save tissue after heart attack.
Samba BioLogics, Inc. is a preclinical stage biotechnology company based in Vermont. We produce breakthrough agonist biologics that preserve tissue and improve repair after ischemic injury. Our pipeline includes “Cell-Kro,” a biologic drug that promotes engraftment of transplanted progenitor cells, and “VasaPlex,” a biologic that rescues jeopardized cardiac tissue after myocardial infarction.
Our Mission
To harness scientific discovery to heal the people that matter most to you.
Our Vision
To be the world’s leading provider of groundbreaking solutions in regenerative medicine that improve quality of life.
Recent News
View recent company news and industry insights.
Samba BioLogics Selected for MassBio’s Biotech Accelerator, MassBioDrive in Spring 2023 Cohort of Startups
The latest cohort of MassBioDrive, a key initiative of MassBio’s innovation programming designed to support entrepreneurs and startups, was announced today by MassBio and features…
Samba BioLogics, Inc. Awarded NIH SBIR/STTR Program Grant
VasaPlex-based biologics for treatment of reperfusion injury after myocardial infarction.
Samba BioLogics Selected for NIH-sponsored DRIVEN Program
Samba BioLogics, Inc. was selected for the NIH-sponsored DRIVEN Program to commercialize our biologics + IP (incubator at Celdara Medical, LLC; West Lebanon, New Hampshire).